Breakthrough drug shows promise in halting debilitating neurological attacks
NCT ID NCT04201262
Summary
This Phase 3 clinical trial tested whether the drug ravulizumab could safely prevent relapses in adults with neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease that attacks the spinal cord and optic nerves. The study involved 58 participants and compared outcomes to an external placebo group. The main goal was to see if the treatment reduced the number of disease flare-ups and slowed disability progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Aurora, Colorado, 80045, United States
-
Research Site
Fort Collins, Colorado, 80528, United States
-
Research Site
Washington D.C., District of Columbia, 20007, United States
-
Research Site
Miami, Florida, 33136, United States
-
Research Site
Boston, Massachusetts, 02114, United States
-
Research Site
Rochester, Minnesota, 55905, United States
-
Research Site
Jackson, Mississippi, 39216, United States
-
Research Site
St Louis, Missouri, 63110, United States
-
Research Site
Cincinnati, Ohio, 45219, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
Camperdown, 2050, Australia
-
Research Site
Fitzroy, 3065, Australia
-
Research Site
Vienna, 1090, Austria
-
Research Site
Burnaby, British Columbia, V5G 2X6, Canada
-
Research Site
Aarhus, 8200, Denmark
-
Research Site
Strasbourg, 67098, France
-
Research Site
Berlin, 10117, Germany
-
Research Site
Leipzig, 04103, Germany
-
Research Site
München, 81675, Germany
-
Research Site
Cefalù, 90015, Italy
-
Research Site
Gallarate, 21013, Italy
-
Research Site
Naples, 80131, Italy
-
Research Site
Roma, 00133, Italy
-
Research Site
Rome, 00178, Italy
-
Research Site
Chiba, 260-0877, Japan
-
Research Site
Fukuoka, 812-8582, Japan
-
Research Site
Kawagoe-shi, 350-8550, Japan
-
Research Site
Niigata, 951-8585, Japan
-
Research Site
Sendai, 980-8574, Japan
-
Research Site
Sendai, 983-8512, Japan
-
Research Site
Katowice, 40-571, Poland
-
Research Site
Lódz, 90-324, Poland
-
Research Site
Goyang-si, 10408, South Korea
-
Research Site
Seoul, 02841, South Korea
-
Research Site
Seoul, 03722, South Korea
-
Research Site
Seoul, 06351, South Korea
-
Research Site
Seoul, 143-729, South Korea
-
Research Site
Barcelona, 08036, Spain
-
Research Site
Madrid, 28040, Spain
-
Research Site
Málaga, 29010, Spain
-
Research Site
Oxford, OX3 9DU, United Kingdom
Conditions
Explore the condition pages connected to this study.